Technical Analysis for COLL - Collegium Pharmaceutical, Inc.

Grade Last Price % Change Price Change
grade D 15.8 -7.06% -1.20
COLL closed down 7.06 percent on Friday, March 22, 2019, on 1.33 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical COLL trend table...

Date Alert Name Type % Chg
Mar 22 20 DMA Resistance Bearish 0.00%
Mar 22 Fell Below 50 DMA Bearish 0.00%
Mar 22 Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Mar 22 Stochastic Reached Oversold Weakness 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 200 DMA Resistance Bearish -7.06%
Mar 21 Fell Below 20 DMA Bearish -7.06%
Mar 20 200 DMA Resistance Bearish -10.23%
Mar 19 MACD Bearish Signal Line Cross Bearish -8.88%
Mar 19 Inside Day Range Contraction -8.88%

Older signals for COLL ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its lead product candidate is Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The company is also developing COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-196, a morphine formulation for the treatment of pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.
Pharmaceutical Pain Diseases Chemical Compounds Organic Compounds Euphoriants Chronic Pain Morphinans Platform Technology Opioids Attention Deficit Hyperactivity Disorder Ethers Hydrocodone Phenols Oxycodone Oxymorphone Treatment Of Attention Deficit Hyperactivity Disorder
Is COLL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 28.91
52 Week Low 13.1
Average Volume 413,991
200-Day Moving Average 17.809
50-Day Moving Average 16.0128
20-Day Moving Average 17.1255
10-Day Moving Average 17.18
Average True Range 0.9287
ADX 17.05
+DI 19.2328
-DI 27.3031
Chandelier Exit (Long, 3 ATRs ) 16.0939
Chandelier Exit (Short, 3 ATRs ) 17.0261
Upper Bollinger Band 19.3506
Lower Bollinger Band 14.9004
Percent B (%b) 0.2
BandWidth 25.985811
MACD Line 0.2806
MACD Signal Line 0.4535
MACD Histogram -0.1729
Fundamentals Value
Market Cap 467.15 Million
Num Shares 29.6 Million
EPS -3.59
Price-to-Earnings (P/E) Ratio -4.40
Price-to-Sales 40.60
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.09
Resistance 3 (R3) 18.28 17.70 17.71
Resistance 2 (R2) 17.70 17.12 17.61 17.58
Resistance 1 (R1) 16.75 16.76 16.47 16.56 17.45
Pivot Point 16.18 16.18 16.04 16.08 16.18
Support 1 (S1) 15.23 15.60 14.94 15.04 14.15
Support 2 (S2) 14.65 15.24 14.56 14.02
Support 3 (S3) 13.70 14.65 13.89
Support 4 (S4) 13.51